Amandeep Salhotra MD

Associate Professor, Department of Hematology, Hematopoietic Cell Transplantation

1500 Duarte RdDuarte, CA 91010
Phone+1 626-256-4673
Fax+1 626-930-5446

Dr. Salhotra is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Salhotra's full profile Already have an account?

Summary

Dr. Amandeep Salhotra is an oncologist in Duarte, CA and is affiliated with City of Hope's Helford Clinical Research Hospital. He received his medical degree from Maulana Azad Medical College and has been in practice 18 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.

Education & Training

University of Virginia Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2012
St Elizabeth's Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2010
St Elizabeth's Medical CenterResidency, Internal Medicine, 2006 - 2009
Maulana Azad Medical CollegeClass of 1999

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2012 - 2028
VA State Medical License 2010 - 2012
MA State Medical License 2009 - 2011

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Sunrise Ambulatory Care, Allscripts, 2013-2017
CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2013-2017
CMS Meaningful Use Stage 2 Certification Sunrise Acute Care, Allscripts, 2013-2017

Clinical Trials

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation Start of enrollment: 2019 Dec 23
SUSPENDED
PHASE2
Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease Start of enrollment: 2020 May 12
ACTIVE_NOT_RECRUITING
PHASE1
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy Start of enrollment: 2017 Dec 29
RECRUITING
PHASE3
Roles: Contact

Publications & Presentations

PubMed

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients.
Caspian H Oliai, Arpita Gandhi, Rasmus T Hoeg, Lori Muffly, Samer A Srour
Transplantation and Cellular Therapy. 2026-08-21
Hypomethylating agents-venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT.
Diana T Samuels, Brian J Ball, Ni-Chun Tsai, Salman Otoukesh, Shukaib Arslan
Blood Neoplasia. 2026-08-01
Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia.
Tamer Othman, Vaibhav Agrawal, Joo Y Song, Zhaohui Gu, Paul Koller
American Journal of Hematology. 2026-07-23

Abstracts/Posters

Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...
Amandeep Salhotra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administr...
Amandeep Salhotra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) _ Long-Term Follow-up of a Phase 2a Study (KD025-208)
Amandeep Salhotra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023

Press Mentions

From Novel Therapies to First-in-Human Trials, City of Hope Advances Blood Cancer Care at the American Society of Hematology (ASH) Annual ConferenceDecember 8th, 2025
City of Hope to Present Breakthroughs in Blood Cancer, Microbiome Research and Cellular Therapies at ASH 2025December 7th, 2024
Plerixafor Doesn’t Overcome HPC Failure in R-hyperCVAD for Mantle Cell LymphomaSeptember 10th, 2017